Latuda is an atypical antipsychotic developed by Sumitomo, while it is characterized by a chemical structure and an affinity for dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors where it has antagonist effects.
Currently, the companies are in discussions to finalize and execute a mutual agreement establishing a transition plan for the orderly transfer of all development and commercialization rights and activities with respect to Latuda to Sumitomo.
Following the effective date of the termination, Takeda’s right to develop and commercialize Latuda within 26 member states of the European Union (excluding the UK), Switzerland, Norway, Turkey and Russia, will be transferred back to Sumitomo.
Sumitomo Dainippon Pharma president and CEO Masayo Tada said: "We remain committed to ensuring continued access to Latuda for patients in Europe, and to further contributing to the treatment of schizophrenia and other psychiatric disorders.
"We will consider all options, including collaboration with a new partner, for the continued development and commercialization of Latuda in Europe."
The two firms continue to believe that Latuda is an appropriate treatment option for adult patients with schizophrenia with minimal impact on important measures of metabolic health.